Table 2.
Descriptive characteristics of the subjects.
| MIR + | no-MIR | |||
|---|---|---|---|---|
| Test | Control | Test | Control | |
| Number | 20 | 22 | 20 | 20 |
| Gender (male/female) | 12/8 | 11/11 | 14/6 | 16/4 |
| Age (years) (mean ± SD ++) | 67.3 ± 5.4 | 67.1 ± 5.7 | 68.3 ± 5.6 | 63.6 ± 5.9 |
| T2D @ duration (months); median (IQR #) |
56 (40–100) | 32 (15–51) | 100 (59–162) | 110 (69–132) |
| Diabetes status (T2DM/pre-diabetes) * | 13/7 | 18/4 | 19/1 | 19/1 |
| Use of Metformin (yes/no) | 11/9 | 16/6 | 19/1 | 19/1 |
| Use of SU derivatives (yes/no) | 7/13 | 6/16 | 5/15 | 9/11 |
+ MIR: Muscle-Insulin Resistance; ++ SD: Standard Deviation; @ T2D: type 2 diabetes; # IQR: interquartile range of q1–q3. * Based upon diabetes medication at screening.